Truist Financial
PBYI icon

Truist Financial’s Puma Biotechnology PBYI Stock Holding History

Truist Financial’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-109,902
Closed -$770K – 2827
2021
Q3 		$770K Buy
109,902
+1,667
+2% +$12.5K ﹤0.01% 1752
2021
Q2 		$994K Buy
108,235
+7,009
+7% +$71K ﹤0.01% 1660
2021
Q1 		$984K Buy
101,226
+43,867
+76% +$490K ﹤0.01% 1604
2020
Q4 		$589K Buy
57,359
+14,638
+34% +$148K ﹤0.01% 1775
2020
Q3 		$431K Buy
42,721
+8,339
+24% +$84.9K ﹤0.01% 1803
2020
Q2 		$359K Buy
34,382
+3,149
+10% +$32.6K ﹤0.01% 1824
2020
Q1 		$264K Buy
31,233
+13,463
+76% +$131K ﹤0.01% 1939
2019
Q4 		$155K Buy
+17,770
New +$147K ﹤0.01% 2387

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Truist Financial's PBYI Position: Q4 2021 in Review

Truist Financial sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 109,902 shares — an estimated $770K sold.

Truist Financial first reported a position in PBYI in Q4 2019 and held it in 8 quarters. The position peaked at $994K in Q2 2021. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • Truist Financial reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Truist Financial sold 109,902 Puma Biotechnology shares in Q4 2021, an estimated $770K.
  • Truist Financial first reported a position in Puma Biotechnology in Q4 2019 and held it in 8 quarters.
  • Truist Financial's Puma Biotechnology position peaked at $994K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Truist Financial's 13F filing for Q4 2021, filed 14 Feb 2022.